Eiger BioPharmaceuticals CEO and leadership

David Cory is an entrepreneur and industry veteran with 25-years experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational, transactional, and financial success.Mr. Cory is currently the President and CEO of Eiger BioPharmaceuticals since 2008. He is responsible for negotiating Eiger’s multiple product licenses from Merck and Astra Zeneca. Cory was previously President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail Pharmaceuticals for $160 million in 2008. Cory was Co-Founder and Chief Commercial Officer at CoTherix, an Orphan Pulmonary Hypertension company, which was acquired by Actelion for $425 million in 2006. Cory began his start up career as Senior Vice President of Commercial Operations at InterMune, a public biotechnology company focused on developing Orphan products for Idiopathic Pulmonary Fibrosis. He was as a key executive in the InterMune IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. Mr. Cory spent the first 12 years of his career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline leading teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, where he directed 10 pharmaceutical product launches and the commercialization of 20 brands.David Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masters Degree in Business Administration from the University of Maryland.

Successful biopharma leader with over 25 years of broad commercial experience across numerous therapeutic areas

- Solid record building companies from the ground up

- Successful track record of developing high-performing teams

- Extensive talent network across many functional areas, including world class sales teams

- Possess deep relationships to deliver turnkey commercial teams

- Strong linkage between commercial and science, team-centric approach

Sri Ryali is a Chief Financial Officer at EIGER BIOPHARMACEUTICALS INC and Head:R&D at Onyx Pharmaceuticals and is based in Thousand Oaks, California. She has worked as Sr Director:Finance at Aimmune Therapeutics; VP:Finance at Aimmune Therapeutics; and Senior Manager, Finance at Amgen. Sri attended UCLA Anderson School of Management.

David Cory is an entrepreneur and industry veteran with 25-years experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational, transactional, and financial success.Mr. Cory is currently the President and CEO of Eiger BioPharmaceuticals since 2008. He is responsible for negotiating Eiger’s multiple product licenses from Merck and Astra Zeneca. Cory was previously President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail Pharmaceuticals for $160 million in 2008. Cory was Co-Founder and Chief Commercial Officer at CoTherix, an Orphan Pulmonary Hypertension company, which was acquired by Actelion for $425 million in 2006. Cory began his start up career as Senior Vice President of Commercial Operations at InterMune, a public biotechnology company focused on developing Orphan products for Idiopathic Pulmonary Fibrosis. He was as a key executive in the InterMune IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. Mr. Cory spent the first 12 years of his career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline leading teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, where he directed 10 pharmaceutical product launches and the commercialization of 20 brands.David Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masters Degree in Business Administration from the University of Maryland.

David Cory is an entrepreneur and industry veteran with 25-years experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational, transactional, and financial success.Mr. Cory is currently the President and CEO of Eiger BioPharmaceuticals since 2008. He is responsible for negotiating Eiger’s multiple product licenses from Merck and Astra Zeneca. Cory was previously President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail Pharmaceuticals for $160 million in 2008. Cory was Co-Founder and Chief Commercial Officer at CoTherix, an Orphan Pulmonary Hypertension company, which was acquired by Actelion for $425 million in 2006. Cory began his start up career as Senior Vice President of Commercial Operations at InterMune, a public biotechnology company focused on developing Orphan products for Idiopathic Pulmonary Fibrosis. He was as a key executive in the InterMune IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. Mr. Cory spent the first 12 years of his career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline leading teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, where he directed 10 pharmaceutical product launches and the commercialization of 20 brands.David Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masters Degree in Business Administration from the University of Maryland.

Successful biopharma leader with over 25 years of broad commercial experience across numerous therapeutic areas

- Solid record building companies from the ground up

- Successful track record of developing high-performing teams

- Extensive talent network across many functional areas, including world class sales teams

- Possess deep relationships to deliver turnkey commercial teams

- Strong linkage between commercial and science, team-centric approach